Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Lipocine Q2 EPS $(0.68) Misses $(0.64) Estimate

Author: Benzinga Newsdesk | August 10, 2023 08:12am
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.64) by 6.25 percent. This is a 11.48 percent decrease over losses of $(0.61) per share from the same period last year.

Posted In: LPCN

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist